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SELDI-based proteomic profiling of body fluids is currently in widespread use for cancer biomarker discovery. We have successfully
used this technology for the diagnosis of hepatocellular carcinoma (HCC) in hepatitis C patients and now report its application to
serial serum samples from 37 hepatitis C patients before development of HCC, with HCC and following radiofrequency ablation of
the tumour. As with alpha-fetoprotein, an accepted biomarker for HCC, we hypothesised that HCC-associated proteomic features
would ‘return to normal’ following successful treatment and the primary aim of our study was to test this hypothesis. Several SELDI
peaks that changed significantly during HCC development were detected but they did not reverse following treatment. These data
may be interpreted to suggest that the characteristic SELDI profile is not linearly related to tumour burden but may result from the
progression of underlying liver disease or from the emergence of precancerous lesions. b2-Microglobulin, a protein previously
reported to be markedly elevated in patients with HCV related HCC, was also the most significantly HCC associated proteomic
feature (m/z 11720) in this study.
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Early diagnosis remains the key to effective therapy of HCC. When
diagnosed below the size of 3cm several surgical or ablative
options are available which are potentially curative (DeMatteo
et al, 1999; Belghiti, 2005; Jansen et al, 2005). However, symptoms
seldom develop in patients with these small tumours with the
result that relatively few patients are suitable for such treatment
options. There is, therefore, considerable interest in presympto-
matic detection by surveillance of high-risk groups (Liaw et al,
1986; Colombo et al, 1991; Chalasani et al, 1999; McMahon et al,
2000; Mok et al, 2005). Although there is no conclusive evidence
(in terms of reduction of disease-specific mortality) that surveil-
lance is effective, it is nonetheless widely practiced (Chalasani et al,
1999) and there is no doubt that such programmes do result in the
detection of small tumours (Chalasani et al, 1999; Mok et al, 2005).
The two currently applied approaches to early detection are serial
estimation of serum alpha fetoprotein (AFP, a serological tumour
marker for HCC) and ultrasound examination. However, the
former is so insensitive that many have questioned its usefulness,
and indeed a recent international consensus statement has
suggested that AFP should no longer be used for this purpose
(Sherman, 2001; Trevisani et al, 2001; Anon, 2005).
Although a non-invasive test would clearly be useful, at present
there does not seem to be any other serological marker that could
improve on AFP and alternative strategies need to be investigated.
One such approach is proteomic profiling (Adam et al, 2002; Li
et al, 2002; Kozak et al, 2003; Poon et al, 2003; Chen et al, 2004;
Paradis et al, 2005; Schwegler et al, 2005; Yang et al, 2005; Ward
et al, 2006a–c). We and other groups have suggested that patients
with HCC may express a characteristic protein ‘signature’ even in
the case of small tumours (Poon et al, 2003; Paradis et al, 2005;
Schwegler et al, 2005; Ward et al, 2006a–c). These signatures are
customarily detected using Surface-Enhanced Laser Desorption/
Ionisation (SELDI) technology, which permits the mass spectrum
of a specific subset of serum proteins to be compared between
cancer and non-cancer patients using various pattern recognition
programmes. While there has been considerable controversy about
the robustness of this approach, particularly with regard to its
reproducibility and the techniques used to validate results
(Diamandis, 2004; Petricoin et al, 2004; Ransohoff, 2004), a large
body of evidence does suggest that such signatures are detectable
(Adam et al, 2002; Li et al, 2002; Kozak et al, 2003; Poon et al, 2003;
Chen et al, 2004; Paradis et al, 2005; Schwegler et al, 2005; Yang
et al, 2005; Ward et al, 2006a–c), even if clinical utility remains to
be convincingly shown.
We have previously assessed the validity of this approach by
testing the signature on a blinded ‘validation data set’, held
externally to the Unit undertaking the SELDI analysis (Ward et al,
2006b), A second validation method is to determine the changes
consequent upon effective treatment, and changes that occur prior
to clinical presentation. In the case of AFP, the classical biomarker
for HCC, such changes are well documented. Prior to clinical
presentation there is a steady exponential rise (with a typical
doubling time of around 30 days) in AFP levels. After effective
treatment levels fall immediately with a half life of around 5 days
(Johnson and Williams, 1980).
Revised 18 July 2006; accepted 15 September 2006; published online 24
October 2006
*Correspondence: Professor PJ Johnson; E-mail: p.johnson@bham.ac.uk
British Journal of Cancer (2006) 95, 1379–1383
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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previously defined and validated characteristic proteomic signa-
tures (Ward et al, 2006b), we now examine the changes that occur
before the clinical presentation of HCC and after effective
treatment, testing the hypothesis that the ‘signature’ will behave
like a classical tumour marker, and return towards normal.
PATIENT AND METHODS
Sample collection
Serum samples were collected between May 1994 and January 2005
at Jean Verdier Hospital, Bondy, France. Sample collection was
officially registered and all patients gave informed consent. Sera
were stored at  801C. All patients were hepatitis C positive and
HCC was diagnosed histologically or non-invasively, according
to the EASL Barcelona Conference criteria (Bruix et al, 2001).
Samples were transported on dry ice to the University of
Birmingham, UK, for analysis in November 2005, defrosted and
multiple 20ml aliquots taken and stored at  801C pending SELDI
analysis. Quality control (QC) samples were prepared by mixing
equal volumes of serum from 27 healthy individuals and stored as
multiple aliquots at  801C.
Study design
We studied 91 samples from 37 patients with HCC (age range 47–
83, median age 63 years, 22 male patients and 15 female patients).
Thirty-eight samples were taken on average 38 months (range
8–123 months) before the diagnosis of HCC, 35 samples taken
once HCC had become clinically evident and 18 sera taken on
average 15 months (range 1–52 months) after treatment. Tumours
ranged from 10 to 45mm in diameter. In all cases, treatment was
on the basis of radiofrequency ablation. All of the post-treatment
samples were from patients considered to have achieved complete
local control.
Independent duplicate SELDI spectra were collected for all
serum samples using Cu
2þ loaded IMAC30 proteinchip arrays.
Samples were processed using 96-well bioprocessors and the
sample order on each bioprocessor was randomised with
duplicates on separate bioprocessors.
SELDI procedure
Sera were analysed using Cu
2þ loaded IMAC30 proteinchip arrays
as described previously (Ward et al, 2006b). Briefly, the
proteinchip arrays were pretreated with CuSO4 followed by a
water rinse and equilibration with binding buffer (500mM NaCl,
100mM NaH2PO4/NaOH (pH 7.0)). Serum samples were diluted 5-
fold with 9 M urea, 2% CHAPS, 50mM Tris/HCl (pH 9.0) followed
by 10-fold dilution in binding buffer. These 50-fold diluted
samples were loaded on proteinchip arrays (100ml per spot) using
a 96-well bioprocessor and incubated at room temperature for 1h.
Following washing with binding buffer and a water rinse 2 1mlo f
50% saturated sinapinic acid in 50% acetonitrile/0.5% trifluoro-
acetic acid was added per spot. The proteinchip arrays were
analysed in a PBSIIc SELDI-TOF equipped with an autoloader
(Ciphergen). Spectra were collected over mass to charge (m/z)
ratios of 0–20000 and 0–200000 (488 laser shots) using laser
intensities of 165 and 210, respectively. Spectra were externally
calibrated in the m/z 0–20000 range using all-in-one peptide
standard (Ciphergen) with added cytochrome C and myoglobin
(Sigma-Aldrich, Poole, Dorset, UK). The m/z 0–200000 range was
calibrated using chymotrypsinogen, bovine serum albumin and
phosphorylase b (Sigma). Spectra were normalised using the total
ion current from m/z 2000–20000 and 20000–200000. Peaks
were selected and clustered using Biomarker Wizard software
(Ciphergen) with the signal to noise ratio 45 for the first pass
and 42 for the second, a cluster mass window of 0.2%, and a
requirement for peaks to be present in 420% of the spectra. These
settings resulted in 125 peaks being selected. The peak intensities
from the duplicate spectra from each sample were averaged and
the resulting peak intensities compared between pre-HCC and
HCC samples and between HCC and post-treatment samples.
To give an estimate of experimental variability the intensities of
82 peaks were compared across 10 replicates of a QC sample
assayed randomly through the study. The average coefficient of
variation of peak intensity was 21%.
Peak identification
The protein underlying the most significantly HCC associated
proteomic feature at m/z 11720 was purified, trypsinised and
identified by LC-MS/MS. SELDI was used to monitor the
purification. A pool of sera with high levels of the m/z 11720
proteomic feature was diluted five-fold with 9 M urea, 2% CHAPS,
50mM Tris/HCl (pH 9.0). This denatured serum was then applied
to Q Ceramic Hyper D anion exchange resin (Pall) and proteins
eluted with washes of decreasing pH. The m/z 11720 peak eluted at
pH 7 and was subsequently applied to a C18 reverse phase column
(Vydac) in 0.1% TFA. Proteins were eluted with an acetonitrile
gradient, and the fractions containing the m/z 11720 peak (54–
60% acetonitrile) were lyophilised and run on a 12% nonreducing
gel using MES buffer (Invitrogen Ltd., Paisley, Scotland). A band
with B12kDa mobility was excised from the gel, digested with
trypsin and the resulting peptides analysed on a Thermofinnigan
Deca XP ion trap mass spectrometer as described previously
(Ward et al, 2006b, c). An ‘immunoSELDI’ approach was used to
confirm that the identified protein corresponded to the SELDI
peak at m/z 11720. A rabbit polyclonal antibody (Sigma: M8523)
raised against human b2-microglobulin was bound to Protein-G
beads and added to serum diluted 10-fold in 150mM NaCl, 20mM
MOPS (pH7.4), 0.1% n-octylglucoside. The SELDI spectrum of the
‘depleted’ serum was compared with that of serum incubated with
Protein-G beads in the absence of antibody. Additionally, the
beads were washed with buffer and then 50% acetonitrile/0.5%
trifluoroacetic acid. The eluted proteins were also analysed
by SELDI.
Estimation of serum AFP concentrations
AFP was measured in all samples in one batch using an AFP
ELISA kit (DRG International) according to the manufacturer’s
instructions.
RESULTS
Comparison of serum profiles before and after
development of clinically detectable HCC
The serum proteome profiles of 27 patients that developed HCC
were measured before and after diagnosis of HCC. The mean time
between paired samples was 45 months (range 8–104 months).
The data were analysed using paired Wilcoxon tests and partial
least squares discriminate analysis (PLSDA) which identifies
discriminatory linear combinations of proteomic features referred
to as latent variables (LVs). Figure 1A shows sample scores on LV1
and LV2 of PLSDA of the proteomic profiles of the pre-HCC and
during-HCC samples – some separation of the two groups is
evident. More importantly, Figure 1B shows that LV1 changes in
the same direction in 26 out of 27 patients; that is there are
consistent proteomic changes that occur in these patients as they
develop HCC. Wilcoxon tests show that 40 proteomic features are
significantly (Po0.05) associated with the occurrence of HCC, 19
of these features with Po0.001. The 10 most statistically significant
HCC associated proteomic features are listed in Table 1.
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proteomic profiles
Serum profiles were compared between paired samples from 18
HCC patients (10 common to the pre-HCC/HCC comparison)
before and at least one month post tumour radiofrequency
ablation (mean time between samples 15 months, range 1–57
months). Active tumour remnants were not detectable in the
arterial phase of the CT scan in the samples from patients in the
post-treatment phase indicating that complete local control of
tumour was achieved in all cases. AFP was elevated in seven of the
patients with HCC. As expected, in these, AFP substantially
decreased following treatment, in six cases reaching either the
reference range or the moderately elevated values frequently
encountered in patients with active HCV cirrhosis (Figure 2). In
the patient without a significant decrease in the serum AFP level,
the level was moderately elevated and probably of extratumoural
origin. Wilcoxon tests were used to identify significant differences
in the SELDI peaks before and after treatment; eight of the 125
proteomic features change with Po0.05 between the pre- and
post-treatment samples, however, none have Po0.001. The mean
intensities of all eight of the peaks with Po0.05 continue the trend
away from pre-HCC levels.
For 10 patients sera were taken before HCC, with established
HCC and post-treatment. All peaks with Po0.05 (Kruskal–Wallis
test) between the before HCC, during-HCC and post-treatment
were used to perform a cluster analysis (Figure 3). The pre-
HCC samples cluster away from the during-HCC and post-
treatment samples indicating that, in the majority of patients, the
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Figure 1 Partial least squares discriminate analysis (PLSDA) of serum
proteomic features before/during HCC. (A) Plots the data using two latent
variables (LV1 and LV2). Filled circles represent pre-HCC samples and
hollow triangles during-HCC samples. (B) Shows the change in LV1
associated with the development of HCC in each patient. PLSDA was
performed using PLS_Toolbox (Version 3.5, Eigenvector Research,
Manson, WA, USA) running in Matlab (Version 7.1, The MathWorks,
Natick, MA, USA).
Table 1 The 10 serum proteomic features most significantly associated
with the onset of HCC
m/z ratio of
proteomic feature P- value
Mean change
intensity (HCC/pre-HCC)
11720 4.8 10
 5 1.82
11925 5.5 10
 5 1.76
2725 7.3 10
 5 0.30
8925 7.3 10
 5 1.25
8180 9.6 10
 5 0.42
5900 0.00013 2.00
2640 0.00021 0.52
6105 0.00021 2.14
3965 0.00027 0.50
6120 0.00027 2.04
The table shows the mass to charge ratio of the peaks, the P-value (Wilcoxon test,
n¼27) and the mean peak intensity in the HCC sera relative to the pre-HCC sera.
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Figure 2 Serum AFP concentrations during HCC and post-treatment.
Log10[AFP] is plotted for two time points (c¼HCC, t¼treated) for seven
patients (labelled A–G).
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Figure 3 Cluster analysis of serum profiles from 10 patients pre-HCC,
during-HCC and post-treatment. The intensities of 32 significant peaks
were used to cluster the samples using the ‘dendrogram’ function in R
(http://www.r-project.org). Each patient is numbered with the pre-HCC
profile represented by a filled circle, the during-HCC profile with a hollow
triangle and the post-treatment by a hollow circle.
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than the pre-HCC profile.
Peak identification
The proteomic feature at m/z 11720 that was highly significantly
altered during HCC (average intensity increase of 80%) was
selected for protein identification. The m/z 11720 peak was
purified by anion exchange chromatography, RP-HPLC and
SDS-PAGE. A band with B12kDa mobility was excised from the
gel and trypsinised. Three tryptic peptides from b2-microglobulin
(sequence mass 11715) were detected (S20NFLNCYVSGFHPS-
DIEVDLLK41,V 49EHSDLSFSK58,V 82NHVTLSQPK91) representing
42% sequence coverage. A peak at m/z 11925 co-purified with
the b2-microglobulin and may correspond to a modified form of
b2-microglobulin. Figure 4 shows the ‘immunoSELDI’ confirma-
tion that the peak at m/z 11720 peak is indeed b2-microglobulin.
DISCUSSION
AFP is currently in widespread use to monitor patients with
chronic liver disease with a view to early detection of HCC
development. However, concentrations are elevated in only about
30% of early HCC (Sherman, 2001). Therefore, there is a great need
for more effective biomarkers for screening, early diagnosis and
monitoring of treatment. Several studies have now suggested that
SELDI profiling of serum can detect HCC in a background of
chronic liver disease (Poon et al, 2003; Paradis et al, 2005;
Schwegler et al, 2005; Ward et al, 2006b). These studies have
usually involved comparison of serum from groups of patients
with and without HCC, and very few ‘longitudinal’ studies,
involving time-dependent proteomic changes in the same patient
have been undertaken. In this study, we show that proteomic
changes correlate with HCC development by comparing samples
from patients before and at the time when the diagnosis of HCC
was established. By comparing different stages of disease progres-
sion in the same group of patients we control for possible
differences (other than those associated with HCC) introduced by
inadvertent patient selection bias. Importantly, this approach can
establish when the proteomic changes commence and if they are
reversed by effective therapy. We find HCC associated proteomic
changes that correlate with the onset of HCC but, unexpectedly,
these changes do not return towards normal (pre-HCC) following
radiofrequency ablation of the tumour.
We have identified one of the 13 proteomic features most
strongly associated with HCC as b2-microglobulin. This is a
particularly reassuring finding since b2-microglobulin has pre-
viously been shown (using immunoturbometric methods) to be
markedly elevated in the serum of hepatitis C patients with HCV-
related HCC when compared to HCV positive patients without
HCC (36716.5mgml
 1 vs 2.370.8mgml
 1; Po0.0001) or healthy
subjects (1.670.4mgml
 1; Po0.0001) (Malaguarnera et al, 2000).
However, it is unlikely that b2-microglobulin alone could act as a
biomarker specifically for HCC as serum levels of b2-microglobu-
lin are also elevated in patients with chronic inflammatory disease,
viral disease (e.g. AIDS) and lymphomas (Cooper and Plesner,
1980). b2-Microglobulin might nonetheless add power to a
multimarker HCC diagnostic test. Furthermore, and in keeping
with our previous experience (Ward et al, 2006a–c), the
identification of this peak as b2-microglobulin suggests that the
profile is, at least in part, characterised by intact proteins rather
than fragments of degraded proteins.
The lack of a ‘return to normal’ following apparently effective
treatment (radiofrequency ablation) is, perhaps, surprising
although there is precedent. Pusztai et al reported that resection
of breast tumours did not produce a return to normal of SELDI
profiles and work from our laboratory indicates that the same is
true for lung cancer (Pusztai et al, 2004; Ward et al, 2006a). The
half-lives of known tumour biomarkers in the serum are in the
order of a few days and several tumour markers, including AFP are
known to return towards normal shortly after successful treatment
(Johnson and Williams, 1980). We found that AFP did indeed fall
in six out of seven patients in this current study. This is not the
case for the SELDI profiles and hence they would not appear to be
useful for monitoring therapy, although a role in diagnosis is not
precluded.
There are several possible explanations as to why the SELDI
profiles still report ‘HCC’ following treatment. The first one would
be that although tumour burden is greatly reduced there is still
sufficient residual disease to maintain the HCC profile. This seems
unlikely since follow-up did not show any short-term local or
distant recurrence in our patients. It is also conceivable that the
SELDI profile reports indirectly on the presence of the tumour by
detecting the host response to the tumour that may persist after
destruction. Another possibility is that SELDI detects changes in
the liver that precede HCC. It is noteworthy that HCV patients with
cirrhosis and HCC are at a very high risk of new primary HCC
when they are not cured of their HCV infection (Yamanaka et al,
2005). Thus, the proteomic changes could be the hallmark of
premalignant lesions that persist after the ablation of the first
malignant tumour.
It seems likely that proteomic changes associated with HCC exist
(in addition to AFP) which ‘return to normal’ following effective
treatment. Although our current study failed to identify such
markers it does identify a SELDI profile that is predictive of the
presence or short-term occurrence of HCC at the moment of
diagnosis. This fact is particularly interesting as most of the
tumours were diagnosed at an early stage making them eligible for
radiofrequency ablation. Various predictive factors of the occur-
rence of HCC have previously been reported and validated such as
age, BMI and the severity of cirrhosis (Nair et al, 2002; Fattovich
et al, 2004). Such factors, mainly epidemiological, are not
susceptible to changes in the short-term. Therefore, it is likely
that SELDI profile changes between prediagnosis and diagnosis
samples reflect other phenomena that might have additional and
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Figure 4 b2-Microglobulin immunoSELDI. IMAC spectra of whole
serum (top), serum depleted with a b2-microglobulin antibody (middle)
and the proteins captured by the antibody (bottom panel).
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further explored by the close follow-up of patients with HCV
cirrhosis who will be screened for HCC and repeated SELDI serum
profiling.
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